Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Tirzepatida y semaglutida son medicamentos muy eficaces para el manejo de la obesidad. Tirzepatida es un agonista de los receptores GIP y GLP-1 de acción prolongada (doble agonismo), mientras que semaglutida es un agonista selectivo de los receptores GLP-1 de acción prolongada (monoagonismo). El ensayo tuvo como objetivo evaluar la eficacia y seguridad de tirzepatida en comparación con semaglutida en adultos con obesidad, pero sin diabetes tipo 2.
Summary The objectives of this study were to explore the relation between body mass index (BMI) and prevalence of diabetes mellitus, hypertension and dyslipidaemia; examine BMI distributions among patients with these conditions; and compare results from two national surveys.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresThe alirocumab (ALI) ODYSSEY clinical trial program recruited patients with hypercholesterolemia, ?70% of whom had atherosclerotic cardiovascular disease (ASCVD) and were at very high ASCVD risk. This analysis evaluated the lipid-lowering efficacy and safety of ALI among patients with or without clinical ASCVD.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
